Britain starts recruiting for real-world COVID antiviral trial


FILE PHOTO: An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS/Files

LONDON (Reuters) - British researchers on Wednesday started recruitment for a clinical trial to test antiviral COVID-19 treatments for use in people early on in the disease who are at higher risks of complications, starting with Merck's molnupiravir.

Britain became the first country in the world to approve molnupiravir, which was jointly developed by U.S.-based Merck & Co Inc and Ridgeback Biotherapeutics, in November.

Britain's Medicines and Healthcare products Regulatory Agency (MHRA) recommended the antiviral pill for use in people with mild to moderate COVID-19 and at least one risk factor for developing severe illness, such as obesity, older age diabetes, and heart disease.

The government said in October it had secured 480,000 courses of the Merck drug, and after its approval, officials said that its rollout would originally be through a trial.

"It is early on in the illness, when people are still being cared for in the community, that treatments for COVID-19 could have their greatest benefit," chief investigator on the trial Professor Chris Butler said.

"This new trial will test whether exciting, new antiviral treatments that are more specific to COVID-19 help people in the community recover faster and reduce the need for treatment in hospital."

The University of Oxford, which is leading the trial, said the first treatment to be investigated would be molnupiravir, also known as Lagevrio, but that it would be able to rapidly evaluate several antiviral treatments over time.

Researchers said that while earlier trials had shown new antivirals to be safe and highly effective in treating COVID-19, the new trial would help generate data on how well they work in populations that have high vaccine coverage, and would inform the broader rollout of the drug.

The study will look to recruit 10,600 people to test whether molnupiravir reduces the need for people to be admitted to hospital.

(Reporting by Alistair Smout; Editing by Kate Holton)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights
   

Next In World

Barbados to hold first election since becoming a republic
North Macedonia and Bulgaria agree to work on issues blocking EU talks
Roads in Sudan's capital barricaded as strike against protest deaths starts
Germany could halt pipeline if Russia attacks Ukraine, Scholz signals
World tourism inched back in 2021, still a fraction of pre-pandemic levels
U.S.'s Blinken to visit Ukraine following Russia talks
Two close aides of Pope Francis test positive for COVID-19, Vatican says
Tongans fear never seeing loved ones again amid communications void
Analysis-Best supporting actor? NATO in secondary role if Russia invades Ukraine
Maltese conservative Metsola becomes third woman to head EU parliament

Others Also Read


Vouchers